Craft

Fertin Pharma

Revenue

KR892.6 M

FY, 2022

Fertin Pharma Summary

Company Summary

Overview
Fertin Pharma is a company that develops and manufactures oral and intra-oral delivery systems. It provides Zapliq, a fast liquefiable tablet, compressed and extruded gum, lozenges, pouch powder, as well as custom delivery systems. The company offers research and development, manufacturing and packaging, sensory optimization, regulatory and compliance, quality control and assurance, and intellectual property services. The company provides solutions used in nicotine, cannabinoids, vitamins and dietary supplements, oral care, energy management, pain management, allergy, and other applications.
Type
Subsidiary
Status
Active
Founded
1915
HQ
Vejle, DK | view all locations
Website
https://fertin.com/
Cybersecurity rating
Sectors

Key People

  • Peter Halling

    Peter Halling, Chief Executive Officer and Member of the Board

  • Michael Thomsen
  • Tobias Vangsgaard Wind

    Tobias Vangsgaard Wind, Vice President BD, Sales & Marketing

  • Helle Egdal

    Helle Egdal, Vice President, People & Culture

Operating MetricsView all

Production Volume, tonnes

3.3K
9.1%

FY, 2021

Units Shipped Yearly

3B

Aug, 2023

Applications

10

Aug, 2023

LocationsView all

4 locations detected

  • Vejle HQ

    Denmark

    Dandyvej 19

  • Langley Township, BC

    Canada

    19720 94a Ave D107

  • Cuncolim, GA

    India

    Plot No. L-10 & L-11

  • Navi Mumbai, MH

    India

    Plot No B-22, Ground Floor, TTC Industrial Area, Rabale MIDC

Fertin Pharma Financials

Summary Financials

Revenue (FY, 2022)
kr892.6M
Gross profit (FY, 2022)
kr25.2M
Net income (FY, 2022)
(kr91.4M)
Cash (FY, 2022)
kr26.4M
EBIT (FY, 2022)
(kr74.8M)

Footer menu